NBIX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 2, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 28, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results with Total Revenue Growing 41% to $1.1 Billion

Nov 2, 2026

8-K

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

Sep 28, 2026

8-K/A

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Jul 31, 2026

8-K

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results and Raises INGREZZA Sales Guidance

Jul 30, 2026

8-K

Neurocrine Biosciences, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 28, 2026

8-K

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

May 18, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

6,944,000 Shares

Feb 19, 2015

424B5

Common Stock

Feb 17, 2015

424B5

8,000,000 Shares

Feb 27, 2014

424B5

7,000,000 Shares

Feb 25, 2014

424B3

Common Stock

Dec 3, 2012

424B5

9,500,000 Shares

Jan 19, 2012

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 31, 2026

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

May 18, 2026

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Apr 29, 2026

SC TO-T/A

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]

Apr 28, 2026

SC TO-T

Form SC TO-T - Tender offer statement by Third Party

Apr 20, 2026

SC TO-C

Form SC TO-C - Written communication relating to an issuer or third party

Apr 6, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 15, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 15, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 9, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 10, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

Neurocrine Biosciences, Inc. NBIX · SEC Filings